Atria Investments LLC Bluebird Bio, Inc. Transaction History

Atria Investments LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 14, 2019	SELL	$59.47 - $93.1 $116,144 - $181,824	-1,953 Closed	0 $0
Q2 2019 Aug 26, 2019	BUY	$75.84 - $105.21 $148,115 - $205,475	1,953 New	1,953 $227,000
Q2 2019 Aug 09, 2019	SELL	$75.84 - $105.21 $132,340 - $183,591	-1,745 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$64.44 - $104.11 $112,447 - $181,671	1,745 New	1,745 $275,000
Q4 2018 Feb 12, 2019	SELL	$59.1 - $93.26 $91,723 - $144,739	-1,552 Closed	0 $0
Q3 2018 Oct 09, 2018	BUY	$88.86 - $117.49 $137,910 - $182,344	1,552 New	1,552 $216,000
Q4 2017 Jan 16, 2018	SELL	$81.25 - $130.7 $124,231 - $199,840	-1,529 Closed	0 $0
Q3 2017 Oct 12, 2017	BUY	$57.74 - $91.42 $88,284 - $139,781	1,529	1,529 $210,000

112

61.5M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $485M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Atria Investments LLC, based on Form 13F filings with the SEC.

Stay updated on Atria Investments LLC with notifications on news.